MetaVia Inc. (Nasdaq: MTVA) is gaining investor attention following a string of clinical and corporate milestones across its cardiometabolic pipeline. In recent months, the company closed a $10 million private placement, presented positive Phase 2a data for DA-1241 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL Congress 2025, and reported additional top-line results from its Phase 1 study of DA-1726 in obesity, showing strong dose-dependent effects on weight loss. President and CEO Hyung Heon Kim shared deeper insights into these programs during MetaVia’s presentation at the June 12 Life Sciences Investor Forum, positioning the company as an emerging player in metabolic disease innovation.
DA-1726 Continues to Show Best-in-Class Potential
Kim outlined the progress of DA-1726, MetaVia’s lead dual GLP-1/glucagon receptor agonist for obesity. In a four-week Phase 1 study, the therapy produced a mean body weight reduction of 4.3 percent and a maximum of 6.3 percent at the 32-mg. dose. Importantly, this was achieved without dose titration and with no treatment-related discontinuations. “There were no serious adverse events. This is quite amazing for a dual agonist,” Kim said.
The candidate also showed a 1.4-inch average waist reduction, with weight effects persisting weeks after the final dose. “Once adipose tissue is broken down, it takes time to rebuild. That is how effective the glucagon aspect was,” he added.
A new 48-mg. cohort will start soon to assess maximum tolerated dose, with data expected before year-end. The company will use the findings to finalize the design of a longer-duration study in obesity.
Positioned for Tolerability Differentiation
Kim emphasized the market opportunity for patients who cannot tolerate titration regimens associated with currently approved GLP-1 drugs. “Roughly 20 to 30 percent of patients drop out in the first two months due to tolerability,” he said. MetaVia aims to serve these patients through a streamlined, no-titration approach with DA-1726. A planned future trial will target this specific population, creating what Kim called a potential “off-ramp” from first-line therapies.
DA-1241 Advancing in MASH with Strong Safety Profile
The company is also developing DA-1241, an oral GPR119 agonist, as a treatment for Metabolic Dysfunction-Associated Steatohepatitis (MASH). At the EASL 2025 Congress, MetaVia presented 16-week Phase 2a data demonstrating meaningful reductions in key liver health biomarkers. Alanine aminotransferase (ALT) levels dropped by nearly 23 units. Controlled Attenuation Parameter (CAP) scores improved by 23 dB per meter, indicating reduced liver fat. The FibroScan-AST (FAST) score also declined. “It’s probably better than DPP-4 inhibitors,” Kim noted, citing DA-1241’s anti-inflammatory and glycemic benefits.
Given the FDA’s requirement for biopsy-confirmed endpoints in later-stage MASH studies, MetaVia is actively seeking a development partner to advance the program into Phase 2b or 3 trials. “We are not going to do that alone,” Kim said. “We are looking to partner to expand our coverage and justify the investment.”
Outlook and Catalysts
The next key milestones for MetaVia include the readout of the 48-mg. DA-1726 cohort, as well as updates on combination therapy strategies for obesity. Kim remains confident in the company’s value proposition. “Other biotechs in obesity have not shown this level of weight loss in a four-week study,” he said. “The price is not where we are.”
With differentiated assets, strong early data, and a capital-efficient strategy, MetaVia is positioning itself for broader investor attention as the cardiometabolic landscape continues to shift.
The full presentation is available to view online [HERE].
About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, DA-1241 demonstrated direct hepatic action in addition to its glucose lowering effects.
For more information, please visit www.metaviatx.com.
This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/
The post PRISM Hidden Value Stock to Watch: MetaVia Builds Momentum in Obesity and MASH with Dual-Agonist Results and High-Dose Trial Readout Expected by Year-End appeared first on PRISM MarketView.
